Based in Japan and India. Has led to 1 successful fundraise in Japan. Been working the space of Venture Capital and Private Equity for the last 3 years.

EMERYVILLE, CA, Lights Berkeley, Inc. (BLI), a leader in digital cell biology, today announced the completion of $95 million of financing led by Nikon and backed by existing investors, Sequoia Capital, Walden-Riverwood Ventures, Black Diamond Ventures and Paxion Capital, and joined by new investors, Cota Capital, KTB Network, Atinum Investment, Shangbay Capital, AJS BioTree Healthcare Fund and Varian. BLI has developed a unique nanoscale technology that accelerates drug discovery and development processes by combining bioscience, technology and information. Funds from the latest investment will be used to accelerate cell therapy development and manufacturing solutions, including CAR T and endogenous T-cells, as well as to increase research and development and expansion of commercial activities.

Berkeley Lights’ Beacon Digital Cell Biology Platform is becoming a proven asset for the world’s leading biopharmaceutical companies involved in the discovery and development of large molecular drugs The rapid adoption of the platform has made BLI a leader in cell line development because the technology allows companies to accelerate timelines and simplify their workflows. In addition, the platform’s flexibility has given rise to an advanced antibody discovery workflow that can utilize primary plasma cells and accelerate the process from more than a month to a single day. The flexibility and precision of BLI technology drives the interest of cell therapy manufacturers in their search for innovative solutions to scale their therapies. The funding will accelerate BLI’s efforts in cell therapy development and manufacturing technology and expand its current product offerings to meet the needs of the company’s growing customer base.

‘This investment by new and past investors is a testament to the significant steps that BLI has already taken to transform the future of drug discovery and development with our digital cell biology platform. In the past 12 months, we’ve more than doubled the rate of adoption of our Beacon platform, and we’ve only just begun,” said Eric Hobbs, Ph.D. D. D. , CEO of Berkeley Lights ‘As we continue to strengthen the global presence of our technology, we will focus on adding platform capabilities that will ultimately make personalized cell therapy accessible to all. ”

‘Our continued support of Berkeley Lights speaks to growing evidence that the company’s technology is in the process of revolutionizing drug discovery and development,’ said Yasuyuki Okamoto, Senior Vice President and Director, Healthcare Business Unit, Nikon Corporation. ‘We look forward to the continued adoption of their digital cell biology platform by the biotechnology and pharmaceutical industries around the globe, as well as the development of additional capabilities that will accelerate the discovery and development of life-saving therapeutics. ”

More than half of the top 25 global pharmaceutical companies have adopted the Beacon platform. With BLI technology, these customers are seeing improvements in their workflow and the potential of digital cell biology to transform the industry. Two recent customer studies show a reduction in time and resources for the development of clonal cell lines and show that BLI technology provides deeper insight into cellular characteristics compared to standard cellular methods. These studies, published in Nature Communications Biology and Biotechnology Processing, evaluated the use of the Beacon platform for the selection of monoclonal cell lines from CRISPR-modified T-cells and CHO cells for commercial production, respectively.

The Beacon platform delivers exceptional efficiencies to current cell biology processing and accelerates discovery and development by using optofluid lighting technology to individually isolate, culture, perform assays and export thousands of live cells in conjunction with visual and digital monitoring. The rich digital and analytical insights provided allow scientists to make more informed choices so that they can select and retrieve the best cells, leading to more consistent and potent therapeutic production within a dramatically reduced timeframe.

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Berkeley%20Lights/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co

Leave a Reply

Your email address will not be published. Required fields are marked *